Physician profile
Michael O Stuart
NPI 1770506735
$3,890.69
in general payments reported to CMS, 2019-2025
15 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $319 · 2021: $544 · 2022: $678 · 2023: $627 · 2024: $429 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,827.91 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $626.31 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $546.14 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $245.60 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Emd Serono, INC. | $152.86 | 2021-2025 | Serostim |
| Janssen Scientific Affairs, LLC | $116.72 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $109.21 | 2021-2024 | Trogarzo, Egrifta |
| Bayer Healthcare Pharmaceuticals INC. | $78.36 | 2023-2025 | |
| Napo Pharmaceuticals INC | $55.71 | 2019-2020 | |
| Dynavax Technologies Corporation | $41.13 | 2024-2025 | Heplisav-B |
| Dexcom, INC. | $25.60 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $20.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.89 | 2023 | |
| Glaxosmithkline, LLC. | $15.03 | 2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $13.09 | 2023 | Emgality, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.